Skip to content

Lenire launches across Hungary

Man in maroon shirt using the Lenire device

Neuromod Devices has reached an agreement with Tinnitus Klinika kft, a provider of specialist tinnitus care, to make its Lenire device available in Hungary.

Landmark research into the prevalence of tinnitus in Europe was published in renowned scientific journal, The Lancet, in late 2021. It found that prevalence of any tinnitus was 14.7%i, which could mean that 1.4 million Hungarians experience the condition.

Through this distribution agreement, Tinnitus Klinika’s specialist team has exclusive licence from Neuromod to provide Lenire throughout Hungary to suitable patients for the treatment of their tinnitus.

“Tinnitus Klinika’s partnership with Neuromod is a significant step forward for our tinnitus patients. I’m delighted to be able to provide an evidence-based treatment option that has seen encouraging patient outcomes in large-scale clinical trials and in the real world as part our suite of services for people living with the condition. I’m looking forward to working closely with Neuromod’s team to achieve the best possible patient outcomes in our clinics,”

explains Tamás Nagy, CEO at Tinnitus Klinika

Tinnitus Klinika’s team have been providing specialist care for people living with tinnitus since it was founded in 2008 by Tamás Nagy, who holds a degree in Audiology from Oxford-Brookes University. The organisation operates 3 clinics in Hungary at Czeizel Institute in Budapest, Hallomás Center in Veszprém, and at Debrecen University in partnership with the University’s Medical school. Tinnitus Klinika offers a suite of therapeutic interventions for people with tinnitus, which now includes Lenire, and has facilitated research of these interventions in their clinical practices under the guidance of the organisation’s Advisory Board.

“I’m delighted to work with Tinnitus Klinika to make Lenire available to people living with tinnitus in Hungary. Tinnitus is globally recognised as a significant healthcare challenge and many people living with the condition have unmet clinical needs. Tinnitus specialists like Tinnitus Klinika deeply understand the needs of tinnitus patients and we’re proud to be able to support them in improving therapeutic outcomes for their patients,”

explains Dr Ross O’Neill, Founder and CEO of Neuromod Devices.

In the last 12 months Neuromod has expanded availability of Lenire in Europe, launching it in Denmark, Norway, Spain, Switzerland, and the UK. Earlier in 2022 the results of an independent real-world analysis were published in the peer-reviewed scientific journal, Brain Stimulation, demonstrating the safety and efficacy of the Lenire device for improving symptoms in tinnitus patients. The study found that 85% of tinnitus patients experienced a reduction in their tinnitus symptoms, as measured by THIii, following six to 12 weeks of treatment using Lenireiii.

The device has also been used in large-scale clinical trials with over 500 patients. The second of these clinical trials was recently published in Nature – Scientific Reports. The results of this trial showed greater average improvement in tinnitus symptoms than the first trial due to optimised treatment plans for participantsiv. 95% of treatment-compliant participants reported an improvement in their tinnitus symptomsiv. 91% of treatment-compliant participants reported an improvement which sustained at least up to 12 months after treatment had endediv.

See the full list of partner clinics across Europe here.


(i) R. Biswas et al., Tinnitus prevalence in Europe: a multi-country cross-sectional population study, The Lancet Regional Health (2021),

(ii) THI or Tinnitus Handicap Inventory is a clinical standard for measuring the impact of tinnitus on someone’s day-to-day life. Measured on a scale of 100, the higher the score, the greater the impact of tinnitus. Reducing a person’s THI score should correspond to improved quality of life by reducing how their tinnitus is affecting them.

(iii) Buechner A, Lesinski-Schiedat A, Becker P, Lenarz T, Real-world clinical experience with bimodal neuromodulation for the treatment of tinnitus – A case series, Brain Stimulation (2022), doi:

(iv) Conlon et al., Different bimodal neuromodulation settings reduce tinnitus symptoms in a large randomized trial, Sci Rep, (2022)

Subscribe to our Newsletter

Our dedicated newsletter for healthcare professionals will keep you up to date with the Lenire® treatment and research.

In order to subscribe you to our newsletter, we require your consent to send marketing communications to you. Please tick the box below to consent to:

You can unsubscribe from these communications at any time. For more information view our privacy policy.

By clicking subscribe, you consent to allow Neuromod to store and process the personal information submitted above to provide you with the content requested.